Athersys Inc (ATHXQ) Kazanmak

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm's MultiStem cell therapy, a patented and proprietary allogeneic off-the-shelf stem cell product, is its lead platform product for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is being evaluated in several clinical-stage programs. Its advanced program is focused on the treatment of ischemic stroke, which is being evaluated in a registrational trial in Japan, and in a Phase III clinical trial primarily in North America and Europe under a Special Protocol Assessment (SPA). Its clinical development programs are focused on treating neurological conditions, inflammatory and immune disorders, cardiovascular disease, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients.